Are currently available biomarkers useful to discriminate CSU patients not controlled by low dose omalizumab maintenance therapy?

Show more: Authors information and Publication history
Authors Information

Allergology clinic, Clinica San Carlo, Paderno Dugnano, Milan, Italy

Published online: 02 November 2020
Accepted: 16 March 2020
Received: 29 January 2020


In patients with Chronic Spontaneous Urticaria (CSU), low dose omalizumab maintenance therapy is effective in about one half of complete, fast responders to the drug. Omalizumab 150 mg/month was given as maintenance therapy to 21 patients with a history of severe CSU showing a complete (UAS7=0) response to the dose of 300 mg/month. After 2 months of such regimen, patients were divided into controlled (n=14; UAS7=0) and not controlled (n=7; UAS7 > 10) and ESR, CRP, total IgE, and D-dimer were measured. The two groups did not differ in any of the biomarkers considered, nor in disease duration or in pre-treatment UAS7 score. The study confirms that it is possible to halve the dose of omalizumab without any loss of efficacy in a subgroup of patients with CSU but that none of the currently available biomarkers is able to predict which patients will lose disease control following omalizumab dose reduction.

Chronic Urticaria; omalizumab; biomarkers; IgE; D-dimer; therapy.

Table of Content: Vol. 52 (No. 6) 2020 November

European Annals of Allergy and Clinical Immunology ISSN 1764-1489 | © 2024